Salvia Advances MySalvia Implantable Migraine Therapy with Pivotal RECLAIM-II Trial in the US

Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable ...

November 02, 2026 | Monday | Interaction
Element Biosciences Launches AVITI Dx Sequencing Platform Across 10 European Markets

Element Biosciences, Inc. announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under th...

November 02, 2026 | Monday | News
Exogenus Therapeutics Leads €13 Million European Project to Advance EXO-101 for Osteoarthritis

ExoCordOA, a five-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clin...

October 30, 2026 | Friday | News
Philips Launches UniGuide 3D Live Guidance in Europe to Improve Precision in Image-Guided Procedures

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and a pioneer in image-guided therapy, announced the launch of Philips UniGuide...

October 30, 2026 | Friday | News
Axplora Advances Axotecan Development to Strengthen European Exatecan Supply for ADC Manufacturers

As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...

October 30, 2026 | Friday | Interaction
Idorsia and Nxera Pharma Partner to Advance Lucerastat into Phase 3 Trials for Fabry Disease

FAB-KLEAR investigates lucerastat as a potential disease-modifying therapy targeting the kidney manifestations of Fabry disease. Nxera will contribute to ...

October 29, 2026 | Thursday | News
GrOwnValve Achieves Primary Safety Endpoint in First Five Patients in Heart Valve Study

GrOwnValve GmbH, a Berlin-based medical technology company developing personalized heart valves from patients' own tissue, announced the achievement of t...

October 28, 2026 | Wednesday | News
Kos Biotechnology Partners Invests in Golden Age Health to Expand Rare Disease Drug Access in Asia

Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President Kos Biotechnology Partners ("Kos"), a global ...

October 28, 2026 | Wednesday | News
Johnson & Johnson Secures EU Approval for TECVAYLI as Second-Line Multiple Myeloma Treatment

Approval is based on Phase 3 results demonstrating significant progression-free and overall survival benefits, with teclistamab reducing risk of disease ...

October 26, 2026 | Monday | News
Recipharm Expands Sterile Manufacturing Capacity with New Production Line in Portugal

Recipharm expands its sterile manufacturing capacity with a new cream and ointment line at Odivelas, Portugal, able to produce 8 to 15 million units pe...

October 23, 2026 | Friday | News
BioNTech and Gilead Partner to Evaluate Pumitamig and Trodelvy in Phase 3 Breast Cancer Trial

BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-nega...

October 23, 2026 | Friday | News
Spotlight Medical’s myStage Dx Demonstrates Breast Cancer Recurrence Risk Prediction in Independent Study

Spotlight Medical, a company developing AI-powered prognostic tests in oncology, announced results from an independent evaluation of myStage Dx, its CE-IVD...

October 23, 2026 | Friday | News
IBA Treats First Patient in Clinical Trial of ConformalFLASH Proton Therapy for Head and Neck Cancer

IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy so...

October 22, 2026 | Thursday | News
Okomera Partners with Servier to Advance Cancer Drug Development Using Tumour Modelling Technology

Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, softwa...

October 22, 2026 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close